Scheduled Maintenance Notice
Please note that Researcher Profiles will be undergoing scheduled maintenance on Wednesday 7th Oct, from 8:00am to 9:00am. During this time, the Researcher Profiles system will be unavailable. We apologise for any inconvenience and appreciate your understanding.
Select Publications
Journal articles
, 2025, 'Australasian hidradenitis suppurativa management guidelines', Australasian Journal of Dermatology, 66, pp. 75 - 89, http://dx.doi.org/10.1111/ajd.14388
, 2025, 'Unravelling the complex pathogenesis of hidradenitis suppurativa', British Journal of Dermatology, 192, pp. i3 - i14, http://dx.doi.org/10.1093/bjd/ljae238
, 2025, 'Discrepancies in hidradenitis suppurativa lesion characterization by providers and patients', Journal of the European Academy of Dermatology and Venereology, 39, pp. 210 - 220, http://dx.doi.org/10.1111/jdv.19999
, 2025, 'Standardized Protocols for Clinical and Histopathological Characterization of Hidradenitis Suppurativa Tissue Specimens', Journal of Investigative Dermatology, 145, pp. 50 - 55, http://dx.doi.org/10.1016/j.jid.2024.02.041
, 2025, '61257 The Clinical and Molecular Response of Pyoderma Gangrenosum to Interleukin 23 Blockade: Result from a proof-of-concept open-label clinical trial', Journal of the American Academy of Dermatology, 93, pp. AB313 - AB313, http://dx.doi.org/10.1016/j.jaad.2025.05.1236
, 2025, '61380 Predictors of wound healing after surgical deroofing in Hidradenitis Suppurativa', Journal of the American Academy of Dermatology, 93, pp. AB72 - AB72, http://dx.doi.org/10.1016/j.jaad.2025.05.292
, 2025, '62297 Resolution of deep dermal inflammatory lesions with the Nanobody sonelokimab in moderate-to-severe hidradenitis suppurativa (HS): preclinical results and outcomes from the Phase 2 MIRA trial', Journal of the American Academy of Dermatology, 93, pp. AB290 - AB290, http://dx.doi.org/10.1016/j.jaad.2025.05.1146
, 2025, '62305 IHS4-100 responses and other IHS4 outcomes with the IL-17A- and IL-17F-inhibiting Nanobody sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (HS): Week 24 results from the Phase 2 MIRA trial', Journal of the American Academy of Dermatology, 93, pp. AB221 - AB221, http://dx.doi.org/10.1016/j.jaad.2025.05.878
, 2025, '64414 Bimekizumab impact on draining tunnel reduction over 2 years in moderate to severe hidradenitis suppurativa: Results from BE HEARD EXT', Journal of the American Academy of Dermatology, 93, pp. AB137 - AB137, http://dx.doi.org/10.1016/j.jaad.2025.05.546
, 2025, '65 Statin Therapy Is Associated With a Reduced Risk of Autoimmune Blistering Diseases: A Global Retrospective Cohort Study of 172 Million Individuals', Journal of Investigative Dermatology, 145, pp. e42, http://dx.doi.org/10.1016/j.jid.2025.09.083
, 2024, 'Intrinsic factors in the pathogenesis of hidradenitis suppurativa: Genetics, hormones, and the microbiome', Journal of the American Academy of Dermatology, 91, pp. S12 - S16, http://dx.doi.org/10.1016/j.jaad.2024.08.052
, 2024, 'Predictors of wound healing after surgical deroofing in Hidradenitis Suppurativa', Australasian Journal of Dermatology, 65, pp. 636 - 641, http://dx.doi.org/10.1111/ajd.14375
, 2024, 'Quality-of-life evaluation in hidradenitis suppurativa in Australia: Validation and outcomes of the HiSQOL questionnaire', Australasian Journal of Dermatology, 65, pp. 630 - 635, http://dx.doi.org/10.1111/ajd.14370
, 2024, 'Response to adalimumab in Caucasian and Asian patients with hidradenitis suppurativa: A retrospective cohort study of an Australian cohort stratified by patient-reported ethnicity', Australasian Journal of Dermatology, 65, pp. 560 - 566, http://dx.doi.org/10.1111/ajd.14343
, 2024, 'Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer', The New England Journal of Medicine, 391, pp. 1413 - 1425, http://dx.doi.org/10.1056/nejmoa2403365
, 2024, 'Proof-of-concept study exploring the effect of spesolimab in patients with moderate-to-severe hidradenitis suppurativa: A randomized double-blind placebo-controlled clinical trial', British Journal of Dermatology, 191, pp. 508 - 518, http://dx.doi.org/10.1093/bjd/ljae144
, 2024, 'Lichenoid drug reaction to technicium-99: a case report and review of the literature', International Journal of Women S Dermatology, 10, http://dx.doi.org/10.1097/JW9.0000000000000179
, 2024, 'A systematic review of case–control studies of cytokines in blister fluid and skin tissue of patients with Stevens Johnson syndrome and toxic epidermal necrolysis', Australasian Journal of Dermatology, 65, pp. 491 - 504, http://dx.doi.org/10.1111/ajd.14329
, 2024, 'An analysis of a 2 × 2 Keyfitz–Kranzer type balance system with varying generalized Chaplygin gas', Physics of Fluids, 36, pp. 096132, http://dx.doi.org/10.1063/5.0231413
, 2024, 'Drug survival of biologics in hidradenitis suppurativa: A systematic review and meta-analysis', Journal of the American Academy of Dermatology, 91, pp. 170 - 172, http://dx.doi.org/10.1016/j.jaad.2024.03.028
, 2024, 'Economic Evaluation of HLA-B*15:02 Genotyping for Asian Australian Patients with Epilepsy', JAMA Dermatology, 160, pp. 631 - 640, http://dx.doi.org/10.1001/jamadermatol.2024.1037
, 2024, 'Tissue comparability and bias in hidradenitis suppurativa transcriptomic studies', Proceedings of the National Academy of Sciences of the United States of America, 121, http://dx.doi.org/10.1073/pnas.2404503121
, 2024, 'Infectious Disease Screening prior to Systemic Immunomodulatory Therapy in Hidradenitis Suppurativa: Consensus Guidelines from the Asia-Pacific Hidradenitis Suppurativa Foundation', Dermatology, 240, pp. 494 - 506, http://dx.doi.org/10.1159/000534575
, 2024, 'Gram-negative anaerobes elicit a robust keratinocytes immune response with potential insights into HS pathogenesis', Experimental Dermatology, 33, http://dx.doi.org/10.1111/exd.15087
, 2024, 'More data are needed to confirm the utility of screening for atypical fibroxanthoma and pleomorphic dermal sarcoma recurrence', Journal of the American Academy of Dermatology, 90, pp. e171 - e173, http://dx.doi.org/10.1016/j.jaad.2023.11.064
, 2024, 'Understanding multi-kinase inhibitor-associated cutaneous ulcers may provide molecular insights into the aetiology of pyoderma gangrenosum: A comment on Jeon et al.', Australasian Journal of Dermatology, 65, pp. e81 - e84, http://dx.doi.org/10.1111/ajd.14221
, 2024, 'Alterations to the Hidradenitis Suppurativa Serum Proteome with Spleen Tyrosine Kinase Antagonism: Proteomic Results from a Phase 2 Clinical Trial', Journal of Investigative Dermatology, 144, pp. 786 - 793.e1, http://dx.doi.org/10.1016/j.jid.2023.10.005
, 2024, 'Comment on Kridin et al.—Considering both relative and absolute risk differences in infection risk between biologics classes in patients with psoriasis', Journal of the European Academy of Dermatology and Venereology, 38, pp. e351 - e353, http://dx.doi.org/10.1111/jdv.19615
, 2024, 'Global consensus process to establish a core dataset for hidradenitis suppurativa registries', British Journal of Dermatology, 190, pp. 510 - 518, http://dx.doi.org/10.1093/bjd/ljad454
, 2024, 'The serum proteome of pyoderma gangrenosum is more expansive than that of hidradenitis suppurativa', Journal of the European Academy of Dermatology and Venereology, 38, pp. e348 - e350, http://dx.doi.org/10.1111/jdv.19611
, 2024, 'Hidradenitis suppurativa: New insights into disease mechanisms and an evolving treatment landscape', British Journal of Dermatology, 190, pp. 149 - 162, http://dx.doi.org/10.1093/bjd/ljad345
, 2024, 'Rapid Attenuation of B-Cell and IFN-γ–Associated Chemokines in Clinical Responders to Jak Inhibition with Upadacitinib in Hidradenitis Suppurativa', Journal of Investigative Dermatology, 144, pp. 416 - 419.e5, http://dx.doi.org/10.1016/j.jid.2023.07.023
, 2024, 'Clinical reports: the overarching home for case series and case reports in the BJD', British Journal of Dermatology, 190, pp. 1 - 2, http://dx.doi.org/10.1093/bjd/ljad301
, 2024, 'Laser capture microdissection provides a novel molecular profile of human primary cutaneous melanoma', Pigment Cell and Melanoma Research, 37, pp. 81 - 89, http://dx.doi.org/10.1111/pcmr.13121
, 2024, 'Mast cells are upregulated in hidradenitis suppurativa tissue, associated with epithelialized tunnels and normalized by spleen tyrosine kinase antagonism', Experimental Dermatology, 33, http://dx.doi.org/10.1111/exd.14894
, 2024, '276 Full Spectrum Town Hall Meetings - Advancing Clinician-Patient-Researcher Engagement for Hidradenitis Suppurativa (HS)', Journal of Clinical and Translational Science, 8, pp. 84 - 84, http://dx.doi.org/10.1017/cts.2024.252
, 2024, '52676 Safety and efficacy over one year of spesolimab treatment in patients with hidradenitis suppurativa (HS): Interim analysis of an open-label extension (OLE) study', Journal of the American Academy of Dermatology, 91, pp. ab83, http://dx.doi.org/10.1016/j.jaad.2024.07.337
, 2024, '52756 Bimekizumab impact on draining tunnels in patients with moderate to severe hidradenitis suppurativa: Pooled 48-week data from BE HEARD I & II', Journal of the American Academy of Dermatology, 91, pp. ab144, http://dx.doi.org/10.1016/j.jaad.2024.07.575
, 2024, 'Economic evaluation of HLA-B*15:02 genotyping in Asian Australian epilepsy patients', Clinical Medicine, 24, pp. 100131, http://dx.doi.org/10.1016/j.clinme.2024.100131
, 2024, 'Impact du bimékizumab sur le nombre de lésions par région anatomique dans l’hidradénite suppurée modérée à sévère : résultats à la semaine 48 de BE HEARD I&II', Annales de Dermatologie et de Vénéréologie - FMC, 4, pp. a361, http://dx.doi.org/10.1016/j.fander.2024.09.427
, 2024, 'Stereotactic Body Radiotherapy for Oligoprogression in Castration-Resistant Prostate Cancer: Early Toxicity Analysis of the TRAP Trial', Clinical Oncology, 36, pp. 585 - 592, http://dx.doi.org/10.1016/j.clon.2024.06.047
, 2023, 'Attenuated PBMC Cytokine Production in Hidradenitis Suppurativa May Be Indicative of Cellular Exhaustion, Providing Novel Biomarkers, and Future Therapeutic Potential', Journal of Investigative Dermatology, 143, pp. 2334 - 2337, http://dx.doi.org/10.1016/j.jid.2023.05.020
, 2023, 'Resident cutaneous memory T cells: a clinical review of their role in chronic inflammatory dermatoses and potential as therapeutic targets', British Journal of Dermatology, 189, pp. 656 - 663, http://dx.doi.org/10.1093/bjd/ljad303
, 2023, 'Human dermal fibroblast subpopulations and epithelial mesenchymal transition signals in hidradenitis suppurativa tunnels are normalized by spleen tyrosine kinase antagonism in vivo', Plos One, 18, pp. e0282763, http://dx.doi.org/10.1371/journal.pone.0282763
, 2023, 'A proof-of-concept open-label clinical trial of spleen tyrosine kinase antagonism using fostamatinib in moderate-to-severe hidradenitis suppurativa', Journal of the American Academy of Dermatology, 89, pp. 694 - 702, http://dx.doi.org/10.1016/j.jaad.2023.05.076
, 2023, 'Efficacy of topical diphencyprone for melanoma in-transit metastases: a systematic review and meta-analysis', Melanoma Research, 33, pp. 434 - 436, http://dx.doi.org/10.1097/CMR.0000000000000914
, 2023, 'Knowledge, attitudes, and perceptions of hidradenitis suppurativa among young adults in Singapore', Jaad International, 12, pp. 72 - 80, http://dx.doi.org/10.1016/j.jdin.2023.03.010
, 2023, 'Obesity and hidradenitis suppurativa: targeting meta-inflammation for therapeutic gain', Clinical and Experimental Dermatology, 48, pp. 984 - 990, http://dx.doi.org/10.1093/ced/llad182
, 2023, 'Reply to Tilotta and Bongiorno: Considering the role of resident cutaneous memory T-cell suppression in providing durable atopic dermatitis remission', Journal of the European Academy of Dermatology and Venereology, 37, pp. e1173 - e1174, http://dx.doi.org/10.1111/jdv.19179
, 2023, 'The impact of psoriasis biologic therapy on HIV viral load and CD4+ cell counts in HIV-positive individuals: A real-world cohort study', Journal of the European Academy of Dermatology and Venereology, 37, pp. 1659 - 1663, http://dx.doi.org/10.1111/jdv.19020